چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | ثنا حمیدی |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | مرکز تحقیقات پزشکی مبتنی بر شواهد EBM |
| کد مقاله | 86629 |
| عنوان فارسی مقاله | مقایسه اثر درمانی پماد تاکرولیموس 0.03% و پماد مومتازون در درمان آتوپیک درماتیت در کودکان یک مطالعه کارازمایی بالینی |
| عنوان لاتین مقاله | The topical ointment therapy in pediatric atopic dermatitis: A randomized clinical trial comparing the efficacy of Tacrolimus0.03% and mometasone ointment. |
| نوع ارائه | سخنرانی |
| عنوان کنگره / همایش | بیست و پنجمین کنگره ملی و یازدهمین کنگره بین المللی سالیانه پژوهش و فناوری دانشجویان علوم پزشکی کشور |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | ارومیه |
| سال انتشار/ ارائه شمسی | 1403 |
| سال انتشار/ارائه میلادی | 2024 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1403/06/15 الی 1403/06/17 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | arcims25.umsu.ac.ir |
| آدرس علمی (Affiliation) نویسنده متقاضی | Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| ثنا حمیدی | اول |
| حمیده هریزچی قدیم | دوم |
| سارا صنیعی | سوم |
| صدیقه جعفری مجد | چهارم |
| هانیه صالحی پورمهر | پنجم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | 1-Introduction: The chronic inflammatory skin disorder known as atopic dermatitis (AD) is characterized by scaly, erythematous, and pruritic lesions. Emollients and avoiding aggravating elements are the mainstays of treatment. Topical corticosteroids are medications that are often used, but extended usage might have negative side effects. Calcineurin inhibitors are an additional therapeutic alternative. This research aims to examine the effectiveness and local adverse effects of tacrolimus 0.03% vs mometasone in treating AD in children in Tabriz. 2- Methods and Materials: Thirty children with atopic dermatitis, ages 2 to 10, participated in a phase 3 clinical trial between May 2019 and April 2020. Two groups participated in the study: one group received tacrolimus ointment as an intervention, while the control group received mometasone ointment. The patients' organ lesions ranged in severity from mild to serious and might measure up to 5 cm. The software SPSS 17 was used to evaluate the gathered data. 3-Results: The results showed that those receiving tacrolimus 0.03% had mean SCORAD scores of 49.2±14.07, 34.2±14.5, and 24.5±19.3 at weeks 0, 3, and 6, respectively (P=0.001). In contrast, the mean SCORAD scores at weeks 0, 3, and 6 for patients who used mometasone ointment were 49.03±10.6, 22.2±18.7, and 11.33±14.3, respectively (P=0.001). Mean SCORAD ratings did not change significantly (P=0.061) between the two groups during the third week of therapy. After six weeks, the mometasone group saw a considerably greater decrease in SCORAD (P=0.043). Treatment-induced pruritus, discomfort, dermatitis, infection, and worsening of post-treatment lesions were similar in both groups. Notably, the tacrolimus group reported a greater frequency of burning feelings (P=0.05). Mometasone treatment resulted in mild atrophy in one patient (p=0.05). When comparing the efficacy of tacrolimus and mometasone in alleviating itching, our results showed no statistically significant difference. 4. Conclusion and discussion: After six weeks, the mean SCORAD score decreased considerably in both groups, but the mometasone group had a larger decline. However, individuals who have not reacted to mometasone or those with sensitive skin regions may benefit more from tacrolimus. |
| کلمات کلیدی | Atopic dermatitis, Treatment, Mometasone, tacrolimus 0.03% |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Gohavi sokhanrani.jpeg | 1403/10/27 | 561548 | دانلود |
| Sabtenam fish.png | 1403/10/27 | 237664 | دانلود |
| fish eskan.png | 1403/10/27 | 231783 | دانلود |
| Best presenter.pdf | 1403/10/27 | 514354 | دانلود |
| Gohavi sherakt.jpeg | 1403/10/27 | 502796 | دانلود |
| congress AD 2024.docx | 1403/10/27 | 1386831 | دانلود |
